Literature DB >> 29699163

Low dose gonadotropin-releasing hormone agonist treatments with early discontinuation for controlled ovarian hyperstimulation in an in vitro fertilization program.

Su-Long Lee1, Jinu-Hwang Su2, Katsuo Ikuta3, Kaoru Suzumori3.   

Abstract

Aim:  The purpose of the present study was to investigate the applicability of a protocol for controlled ovarian hyperstimulation (COH) featuring early discontinuation of low dose gonadotropin-releasing hormone agonist (GnRHa) for ovulation induction for in vitro fertilization (IVF).
Methods:   Four hundred and eighty-seven women undergoing 555 IVF cycles were recruited into the study. Controlled ovarian hyperstimulation was achieved by using either a short protocol of low dose GnRHa (for 5 days only; groups 1 and 2) or a modified long protocol with early discontinuation of GnRHa (groups 3 and 4). Groups 1 and 3 received urinary follicle-stimulating hormone (FSH) and groups 2 and 4 received recombinant FSH. Oocyte retrieval was performed 34 to 36 h after human chorionic gonadotropin (hCG) injection, followed by embryo transfer 3 days later.
Results:   Luteinizing hormone (LH) levels on the hCG injection day were lower with the modified long protocol (groups 3 and 4) than with the short 5-day treatment (groups 1 and 2). There were higher LH levels in group 1 than in groups 2, 3 and 4, resulting in a worse fertilization rate and clinical pregnancy rate. There were no statistically significant differences between groups 2, 3 and 4 in the rates of fertilization, clinical pregnancy and delivery. A higher estradiol (E2) level in group 3 than in groups 1, 2 and 4 resulted in a worse implantation rate.
Conclusion:   Early cessation of GnRHa may not induce a premature LH surge in controlled ovarian hyperstimulation, while a low dose also offers a useful alternative to a long protocol of IVF. Ovarian stimulation with recombinant follicle-stimulating hormone (rFSH) is considered to be favorable in this low dose GnRHa treatment. (Reprod Med Biol 2003; 2: 25-30).

Entities:  

Keywords:  controlled ovarian hyperstimulation; gonadotropin; gonadotropin‐releasing hormone agonist; in vitro fertilization

Year:  2003        PMID: 29699163      PMCID: PMC5906940          DOI: 10.1046/j.1445-5781.2003.00014.x

Source DB:  PubMed          Journal:  Reprod Med Biol        ISSN: 1445-5781


  27 in total

1.  Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome.

Authors:  E Loumaye; P Engrand; C M Howles; L O'Dea
Journal:  Fertil Steril       Date:  1997-05       Impact factor: 7.329

2.  Use of buserelin acetate in an in vitro fertilization program: a comparison with classical clomiphene citrate-human menopausal gonadotropin treatment.

Authors:  B Lejeune; P Barlow; F Puissant; A Delvigne; M Vanrysselberge; F Leroy
Journal:  Fertil Steril       Date:  1990-09       Impact factor: 7.329

Review 3.  Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process.

Authors:  S C Chappel; C Howles
Journal:  Hum Reprod       Date:  1991-10       Impact factor: 6.918

4.  Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval.

Authors:  M I Cedars; E Surey; F Hamilton; P Lapolt; D R Meldrum
Journal:  Fertil Steril       Date:  1990-04       Impact factor: 7.329

5.  Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization.

Authors:  C Alvarez; N Cremades; N Blasco; R Bernabeu
Journal:  Hum Reprod       Date:  1997-11       Impact factor: 6.918

6.  Premature luteinization in controlled ovarian hyperstimulation has no adverse effect on oocyte and embryo quality.

Authors:  G E Hofmann; F Bentzien; P A Bergh; G J Garrisi; M C Williams; I Guzman; D Navot
Journal:  Fertil Steril       Date:  1993-10       Impact factor: 7.329

7.  Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation.

Authors:  A Hazout; D de Ziegler; C Cornel; H Fernandez; C Lelaidier; R Frydman
Journal:  Fertil Steril       Date:  1993-03       Impact factor: 7.329

8.  Sperm characteristics and outcome of human assisted fertilization by subzonal insemination and intracytoplasmic sperm injection.

Authors:  G Palermo; H Joris; M P Derde; M Camus; P Devroey; A Van Steirteghem
Journal:  Fertil Steril       Date:  1993-04       Impact factor: 7.329

9.  Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin.

Authors:  S L Tan; N Maconochie; P Doyle; S Campbell; A Balen; J Bekir; P Brinsden; R G Edwards; H S Jacobs
Journal:  Am J Obstet Gynecol       Date:  1994-08       Impact factor: 8.661

10.  Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program.

Authors:  R Frydman; J Belaisch-Allart; I Parneix; R Forman; A Hazout; J Testart
Journal:  Fertil Steril       Date:  1988-09       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.